Oso Biopharmaceuticals Announces Acquisition of Albuquerque Injectables Business from Catalent

Oso Biopharmaceuticals Manufacturing, LLC ("Oso

Biopharmaceuticals") and Catalent Pharma

Solutions today jointly announced the completion of the purchase of

Catalent´s Albuquerque, New Mexico sterile

injectables manufacturing business. Terms of the transaction, which

became effective May 17, were not disclosed. The Albuquerque business provides cGMP glass vial filling and

lyophilization services for injectable drugs and biologics that are

either approved for commercial marketing or in clinical development. Oso

Biopharmaceuticals will retain all employees associated with the

business and continue to serve all existing customers in North America

and Europe. Dr. Stuart Rose, Chief Executive Officer and President of Oso

Biopharmaceuticals, said, "We are delighted to

have been successful in acquiring Catalent´s sterile injectables

business based in Albuquerque. It fits exceedingly well with our

strategy to build a world class, high quality contract manufacturing

company. We will work tirelessly with the talent pool in Albuquerque to

meet the highest demands and expectations of our global customer base." Altaris Capital Partners, LLC ("Altaris")

a healthcare investment firm, collaborated with Oso Biopharmaceuticals

and provided capital for the transaction. Richard Yarwood, Group President of Sterile Technologies for Catalent

said, "We are pleased to have completed this

planned step in the evolution of our Sterile Technologies business. We

are also pleased that Oso Biopharmaceuticals has acquired this business

as we expect they will continue to provide the facility´s

customers the high degree of quality and compliance they have received

in the past. We also appreciate the commitment Oso Biopharmaceuticals

has demonstrated to the future of the business, and to the dedicated

employees at the site." About Oso Biopharmaceuticals Oso Biopharmaceuticals Manufacturing, LLC is a contract manufacturing

company focused on providing a superior level of service to customers.

With an emphasis on the production of injectable pharmaceutical products

that require special or complex handling, Oso Biopharmaceuticals

understands that attention to detail and service levels are a priority

for its clients. About Altaris Altaris Capital Partners, LLC is an investment firm focused exclusively

on companies operating in the healthcare industry. Altaris is based in

New York and has more than $750 million of assets under management. For

more information, please visit www.altariscap.com. About Catalent Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is one

of the leading providers of advanced technologies, and development

manufacturing and packaging services for pharmaceutical, biotechnology

and consumer healthcare companies in nearly 100 countries. Catalent

applies its local market expertise and technical creativity to advance

treatments, change markets and enhance patient outcomes. Catalent

employs approximately 10,000 at more than 30 facilities worldwide and

generates more than $1.7 billion of annual revenue. For more

information, visit www.catalent.com.